PFE Pfizer Inc
Company Analysis
Latest News
Steve Cohen's Point72 Exits $122M Pfizer Position
In a significant portfolio change, Point72, the investment firm led by Steve Cohen, liquidated its entire stake in Pfizer (PFE). The firm sold all 4.37 million...
Pfizer launches Depo-Provera settlement, addressing $1.2 billion in brain tumor claims
Pfizer established a settlement program to resolve federal lawsuits involving its Depo-Provera birth control shot. Plaintiffs allege the injection caused...
Pfizer and Valneva's Lyme Vaccine Application Advances to EMA Review
Pfizer and Valneva announced the European Medicines Agency (EMA) validated their Marketing Authorization Application for VLA15, an investigational Lyme disease...
Pfizer's second quarter revenue of $15.0B beat estimates, prompting a raised FY2026 outlook.
Pfizer reported second quarter 2026 revenues of $15.0 billion and an adjusted EPS of $0.77, beating analyst expectations. On a GAAP basis, the company reported...
Pfizer Inc Q2 2026 Earnings Preview: What Analysts Expect on August 04, 2026
Pfizer is projected to report Q2 2026 revenue of $14.43 billion and adjusted EPS of $0.68, as the stock trades near $25.10 relative to a $28.75 analyst...
Pfizer’s Litfulo Hits Phase 3 Goals for Vitiligo, Eyes Global Filings
Pfizer reported positive topline results from two Phase 3 trials evaluating Litfulo for nonsegmental vitiligo. The TRANQUILLO and TRANQUILLO 2 studies met...
Sanofi Sues Pfizer and Moderna, Alleging Blockbuster COVID-19 Vaccine Patent Infringement
Sanofi filed lawsuits against Pfizer and Moderna in a New Jersey federal court. The French pharmaceutical company alleges their COVID-19 vaccines infringe upon...
Pfizer freezes Polish air-traffic funds, seeking €1.3B for unpaid vaccines
Pfizer is enforcing a Belgian court ruling ordering Poland to pay €1.3 billion for COVID-19 vaccines. The legal action follows the Polish government's refusal...
Pfizer Rises, AstraZeneca Heart Drug Failure Protects Vyndamax Market
Pfizer shares rose approximately 1% in pre-market trading. The move followed an announcement from AstraZeneca and Ionis Pharmaceuticals regarding the...
Pfizer Downgraded to Hold, Hit by Lung Cancer Drug Trial Setback
HSBC downgraded Pfizer (PFE) from Buy to Hold. The bank lowered its 12-month price target for the stock from $32.00 to $28.00. A Phase 3 trial setback for...
Pfizer GLP-1 drug clears China insurance hurdle, targeting wider patient access
Pfizer’s GLP-1 candidate ecnoglutide passed the National Healthcare Security Administration's preliminary review for China’s national medical insurance...
🟢 PFE is trading 2.5% up today after FDA expands IBRANCE breast cancer indication
PFE is trading 2.5% up at $24.27 after the FDA approved an expanded indication for its breast cancer drug, IBRANCE. • The June 24, 2026, decision allows...
Pfizer Wins FDA Approval for IBRANCE, Cutting Breast Cancer Progression Risk 24%
Pfizer received U.S. Food and Drug Administration (FDA) approval for the expanded use of IBRANCE (palbociclib). The approval covers maintenance treatment for...
🔴 PFE is trading 2% down today after mixed Phase 3 lung cancer trial results
PFE is trading 2% down today at $24.23, extending its recent multi-day slide. Investors are reacting to: • Mixed topline Phase 3 results for Pfizer's...
Pfizer pauses major acquisitions for AI efficiency, targeting stock recovery
Pfizer is pausing large-scale acquisitions to prioritize operational transformation through artificial intelligence. This shift follows the $43 billion...
Pfizer Reaffirms Full-Year 2026 Financial Guidance Amid CFO Transition
Pfizer has reaffirmed its full-year 2026 financial guidance, which was originally introduced on December 16, 2025. The company confirmed its outlook following...
🔴 Pfizer Inc is trading 2.8% down today after CFO departure news
Pfizer Inc is trading at $25.20 (-2.76%) following the announcement that Chief Financial Officer Dave Denton will step down on August 15, 2026. • The company...
Pfizer CFO Dave Denton to Depart; Cecile Guegan Appointed Interim CFO
Pfizer announced that Chief Financial Officer Dave Denton will step down from his role, effective August 15, 2026, to pursue an opportunity outside the...
Pfizer Advances Monthly Obesity Shot, Reporting 15.9% Weight Loss in Trial
Pfizer reported positive Phase 2b study results for berobenatide, an investigational once-monthly weight loss injection. Data presented at the American...
Pfizer’s Braftovi Slashes Cancer Progression Risk by 56% in Phase 3 Trial
Pfizer announced Phase 3 BREAKWATER trial results for BRAFTOVI (encorafenib) at the 2026 ASCO Annual Meeting. The study evaluated the drug combination in...